SPIN 2019
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/01/C1_SPIN_MCR-Cover_2019-1-225x300.png)
Read the full Report (pdf)
Skin Inflammation & Psoriasis International Network
25–27 April 2019, Paris, France
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/06/Figure_IL-17_is_central_to_psoriasis_etc.png)
Treatment goals in psoriasis
CONTENTS
Online First
Aetiology: Triggers and Risk Factors
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/06/Table_Overview_of_genetic_determinants_of_psoriasis.png)
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in Therapy
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/06/Table_Overview_of_safety_events_through_week_56.png)
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/06/Table_Overview_of_adverse_events_and_serious_adverse_etc.png)
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Novel Considerations
Granulomatous rosacea: exploratory histological markers
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/06/Figure_Psoriasiform_dermatitis_with_a_subcorneal_pustule.png)
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Switching infliximab biosimilars safe in treating chronic plaque psoriasis
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/06/Figure_IL-17_is_central_to_psoriasis_etc.png)